Monire Seyed Hashemi1, Nasim Namiranian2, Hemaseh Tavahen1, Abolfazl Dehghanpour1, Mohammad Hadi Rad3, Saeedeh Jam-Ashkezari2, Majid Emtiazy1,4, Mohammad Hashem Hashempur5,6. 1. Department of Persian Medicine, The School of Persian Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. 2. Yazd Diabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. 3. Agricultural and Natural Resource Research and Education Center, Agriculture Research Education and Extension Organization (AREEO), Yazd, Iran. 4. Research Center of Persian Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. 5. Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran, hashempur@gmail.com. 6. Department of Persian Medicine, Fasa University of Medical Sciences, Fasa, Iran, hashempur@gmail.com.
Abstract
INTRODUCTION: Pomegranate is known as a functional food which has multiple health-promoting activities. It has been assessed for patients with metabolic syndrome. Specifically, an antidiabetic activity of its juice and plausible mechanisms for its action have been shown in multitudinous studies. The aim of this study was assessing the effects of complementary treatment with pomegranate seed powder (PSP) oral supplementation on patients with type 2 diabetes mellitus (T2DM). METHODS:Sixty patients were treated for 8 weeks by 5 g PSP or placebo, twice daily. Fasting blood glucose (FBG), glycated hemoglobin (HbA1c), total cholesterol, and triglyceride (TG) were recorded as the outcome measures at the beginning and after the intervention. The findings were analyzed using the independent t test and Mann-Whitney U test. RESULTS: After 8 weeks, the mean differences of FBG, HbA1c, cholesterol, and TG were significantly decreased in the PSP group when compared with the placebo group (p value <0.05). In addition, post-intervention values of FBG and HbA1c were significantly lower in patients treated with PSP compared to the placebo group (p values = 0.02 and 0.01, respectively). However, the latter comparison regarding cholesterol and TG showed no significant differences (p values = 0.51 and 0.26, respectively). CONCLUSION: It seems that complementary treatment with PSP may have beneficial effects on FBG and HbA1c of patients with T2DM. However, its effect on TG and cholesterol was equivocal.
RCT Entities:
INTRODUCTION:Pomegranate is known as a functional food which has multiple health-promoting activities. It has been assessed for patients with metabolic syndrome. Specifically, an antidiabetic activity of its juice and plausible mechanisms for its action have been shown in multitudinous studies. The aim of this study was assessing the effects of complementary treatment with pomegranate seed powder (PSP) oral supplementation on patients with type 2 diabetes mellitus (T2DM). METHODS: Sixty patients were treated for 8 weeks by 5 g PSP or placebo, twice daily. Fasting blood glucose (FBG), glycated hemoglobin (HbA1c), total cholesterol, and triglyceride (TG) were recorded as the outcome measures at the beginning and after the intervention. The findings were analyzed using the independent t test and Mann-Whitney U test. RESULTS: After 8 weeks, the mean differences of FBG, HbA1c, cholesterol, and TG were significantly decreased in the PSP group when compared with the placebo group (p value <0.05). In addition, post-intervention values of FBG and HbA1c were significantly lower in patients treated with PSP compared to the placebo group (p values = 0.02 and 0.01, respectively). However, the latter comparison regarding cholesterol and TG showed no significant differences (p values = 0.51 and 0.26, respectively). CONCLUSION: It seems that complementary treatment with PSP may have beneficial effects on FBG and HbA1c of patients with T2DM. However, its effect on TG and cholesterol was equivocal.
Authors: Kaushik Chattopadhyay; Haiquan Wang; Jaspreet Kaur; Gamze Nalbant; Abdullah Almaqhawi; Burak Kundakci; Jeemon Panniyammakal; Michael Heinrich; Sarah Anne Lewis; Sheila Margaret Greenfield; Nikhil Tandon; Tuhin Kanti Biswas; Sanjay Kinra; Jo Leonardi-Bee Journal: Front Pharmacol Date: 2022-06-08 Impact factor: 5.988